Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade in Myelodysplastic Syndromes (MDS)
NCT00262873Phase 2Completed
- Sponsor
- University of Rochester
- Start
- May 2005
- Primary completion
- Oct 2010
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in myelodysplastic syndrome (MDS), sponsored by University of Rochester. Started May 2005; status: completed.
02
Drugs
bortezomib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00262873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00262873.